Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 2/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | ILK | Q13418 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | LSS | P48449 | 1/20 | 0.32 |
| ▸ | TOP2A | P11388 | 2/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3882724 | 0.93 | ADRB2 (0.34) | ILKMAOBBCHEMAOAACHE | |
| SCHEMBL3882960 | 0.90 | MAPK1 (0.36) | CACNA1BCYP1A2CYP2D6 | |
| SCHEMBL3884661 | 0.83 | MAPK1 (0.37) | CACNA1BMAOAACHECYP1A2CYP2D6 | |
| SCHEMBL3881628 | 0.83 | ILK (0.36) | ILKLSSBCHEMAOAACHE | |
| SCHEMBL3883799 | 0.80 | CACNA1B (0.34) | CACNA1BCACNA1HMAOBLSSTOP2A | |
| SCHEMBL4706181 | 0.78 | CACNA1B (0.35) | CACNA1BCACNA1HMAOBLSSTOP2A | |
| SCHEMBL3881218 | 0.75 | CHRM2 (0.36) | ILKBCHEMAOAACHECYP1A2 | |
| SCHEMBL4695703 | 0.75 | CACNA1H (0.34) | CACNA1BCACNA1HMAOBLSSTOP2A | |
| SCHEMBL5182469 | 0.74 | NR4A2 (0.35) | CACNA1BCACNA1HMAOBLSSTOP2A | |
| SCHEMBL3882099 | 0.73 | MAPK1 (0.36) | CACNA1BCACNA1HMAOAACHECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550498-B2 | 1,2-Diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2009-06-23 | — | — | US | claimed |
| EP-1686989-B1 | USE OF 1,2-DIAZA-DIBENZO[E,H]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GLAXOSMITHKLINE ZAGREB (HR) | 2009-01-14 | — | — | EP | claimed |
| EP-1587807-B1 | 1,2-DIAZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | GLAXOSMITHKLINE ZAGREB (HR) | 2008-06-18 | — | — | EP | claimed |
| US-20070173492-A1 | 1,2-Diaza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2007-07-26 | — | — | US | claimed |
| EP-1587807-A3 | 1,2-DIAZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | Pliva-Istrazivacki Institut D.D.O. (HR) | 2005-11-16 | — | — | EP | claimed |
| EP-1587807-A2 | 1,2-DIAZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | Pliva-Istrazivacki Institut D.D.O. (HR) | 2005-10-26 | — | — | EP | claimed |
| US-20050209296-A1 | 1,2-Diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-09-22 | — | — | US | claimed |
| WO-2003099822-A2 | 1,2-DIAZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | PLIVA - ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2003-12-04 | — | — | WO | claimed |
| US-7550498-B2 | 1,2-Diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2009-06-23 | — | — | US | disclosed |
| EP-1686989-B1 | USE OF 1,2-DIAZA-DIBENZO[E,H]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GLAXOSMITHKLINE ZAGREB (HR) | 2009-01-14 | — | — | EP | disclosed |
| EP-1587807-B1 | 1,2-DIAZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | GLAXOSMITHKLINE ZAGREB (HR) | 2008-06-18 | — | — | EP | disclosed |
| US-20070173492-A1 | 1,2-Diaza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2007-07-26 | — | — | US | disclosed |
| US-20050209296-A1 | 1,2-Diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209296-A1 | 1,2-Diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | TNF, IL1A, IL1B | CACNA1B 1548/4885CACNA1H 1707/4885ILK 4505/4885 |
| US-20070173492-A1 | 1,2-Diaza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | DBH, DDT, BCHE | CACNA1B 425/4885CACNA1H 379/4885ILK 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.